Why the study?
Does aliskiren ameliorate cardiac and renal damage in double-transgenic rats compared to untreated controls and valsartan?
Population
Six-week-old double transgenic rats for human renin and angiotensinogen genes, matched by albuminuria
Comparison
Aliskiren administered from week 6 through week 9 vs Untreated dTGR and valsartan treated rats
Design
Preclinical
Follow-up
3 weeks (from week 6 through week 9)
Authors
Loading...
Aliskiren attenuates cardiorenal injury in this rat model; leaves open translation to human hypertension and requires prospective trials.
Does aliskiren ameliorate cardiac and renal damage in double-transgenic rats compared to untreated controls and valsartan?
In a double-transgenic rat model, the renin inhibitor aliskiren effectively lowered blood pressure and attenuated cardiac and renal damage, comparing favorably to valsartan.
Pilz et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: